CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced the appointment of Margaret Koziel, M.D., as Chief Medical Officer (CMO). Juan Carlos Lopez-Talavera, M.D., Ph.D., who has served as acting CMO since December 2023, will move to an advisory role to Dr.

马萨诸塞州剑桥市（商业新闻短讯）--波士顿制药公司是一家临床阶段的生物制药公司，开发针对严重肝病的分化分子，今天宣布任命医学博士玛格丽特·科齐尔为首席医疗官（CMO）。胡安·卡洛斯·洛佩斯·塔拉维拉（JuanCarlosLopezTalavera），医学博士，博士，自2023年12月起担任代理首席营销官，将担任Dr。

Koziel and the Boston Pharmaceuticals team as the company advances its promising late-stage candidate BOS-580, an investigational long-acting, once-monthly fibroblast growth factor 21 (FGF21) analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)..

科齐尔（Koziel）和波士顿制药（Boston Pharmaceuticals）团队正在推进其有前途的晚期候选药物BOS-580，这是一种研究性长效，每月一次的成纤维细胞生长因子21（FGF21）类似物，用于治疗代谢功能障碍相关的脂肪性肝炎（MASH）。。

“Boston Pharmaceuticals is at an exciting time as we advance our lead program BOS-580 with biopsy results expected soon in patients with stage F2 and F3 disease. We are committed to building a strong organizational structure and leadership team. Dr. Koziel’s rich experience and deep scientific expertise in liver disease are instrumental in achieving our next developmental milestones,” said Sophie Kornowski, CEO of Boston Pharmaceuticals..

波士顿制药首席执行官索菲·科诺夫斯基（SophieKornowski）表示：“波士顿制药正处于一个激动人心的时刻，因为我们推进了领先项目BOS-580，预计F2和F3期患者的活检结果很快就会出来。我们致力于建立一个强大的组织结构和领导团队。科齐尔博士在肝病方面的丰富经验和深厚的科学专业知识有助于实现我们下一个发展里程碑。”。。

“I am excited to join Boston Pharmaceuticals at this pivotal juncture. Backed by a skilled team and strong partnerships, the company is poised to move BOS-580 swiftly and successfully through clinical development to meet patient needs,” said Dr. Koziel.

科齐尔博士说：“我很高兴在这个关键时刻加入波士顿制药公司。在一支技能娴熟的团队和强大的合作伙伴的支持下，该公司准备通过临床开发迅速成功地推进BOS-580，以满足患者的需求。”。

Dr. Koziel brings 16 years of drug development and executive leadership experience to Boston Pharmaceuticals. She previously held CMO positions for Innoviva Specialty Therapeutics, Inc. and Axcella Therapeutics, Inc. She first joined Axcella as head of the company’s development program for MASH before assuming the role of Vice President, Clinical Development and CMO.

科齐尔博士为波士顿制药公司带来了16年的药物开发和高管经验。她之前曾担任Innoviva Specialty Therapeutics，Inc.和Axcella Therapeutics，Inc.的CMO职位。在担任临床开发和CMO副总裁之前，她首先加入Axcella，担任公司MASH开发计划的负责人。

Prior to that, she held several positions of increasing responsibility at Kaleido Biosciences, Vertex, and the Novartis Institute for Biomedical Sciences. From target selection through Phase 4 studies, her work has focused on advancing drug development in hepatology and infectious disease among other therapeutic areas such as oncology, rare diseases, long COVID and immunology..

在此之前，她在Kaleido Biosciences，Vertex和诺华生物医学科学研究所担任了几个越来越重要的职位。从目标选择到第4阶段研究，她的工作重点是推进肝病和传染病的药物开发以及其他治疗领域，如肿瘤学，罕见病，长冠状病毒和免疫学。。

Dr. Koziel also served in academic positions as a professor and assistant vice provost for clinical research at the University of Massachusetts Medical School, and as a staff physician at Beth Israel Deaconess Medical Center and an associate professor of medicine at Harvard Medical School. Her research interests focused on the immune response to hepatitis C virus, as well as advancing clinical care for HIV for which she has received numerous awards.

科齐尔博士还担任过麻省大学医学院临床研究教授和助理副院长的学术职务，以及贝斯以色列女执事医学中心的主任医师和哈佛医学院的医学副教授。她的研究兴趣集中在对丙型肝炎病毒的免疫反应，以及推进艾滋病毒的临床护理，为此她获得了许多奖项。

Dr. Koziel has authored more than 90 publications in journals such as the New England Journal of Medicine and Journal of Clinical Investigation and has served as an associate editor and reviewer for numerous journals. Dr. Koziel obtained her bachelor’s degree and medical degree from Dartmouth College and completed her postgraduate medical training at the New England Deaconess Hospital and Massachusetts General Hospital..

Koziel博士在《新英格兰医学杂志》和《临床研究杂志》等期刊上发表了90多篇出版物，并担任多家期刊的副主编和审稿人。科齐尔博士从达特茅斯学院获得学士学位和医学学位，并在新英格兰女执事医院和马萨诸塞州总医院完成了研究生医学培训。。

About BOS-580

关于BOS-580

BOS-580 is a once-monthly subcutaneous injectable of a long-acting, highly engineered variant of human fibroblast growth factor 21 (FGF21) that regulates various metabolic pathways to decrease liver fat and ameliorate liver inflammation and damage in patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH)..

BOS-580是一种长效，高度工程化的人成纤维细胞生长因子21（FGF21）变体，每月一次皮下注射，可调节各种代谢途径，以减少肝脏脂肪，改善代谢功能障碍相关脂肪性肝炎（MASH）患者的肝脏炎症和损伤，也称为非酒精性脂肪性肝炎（NASH）。。

About Boston Pharmaceuticals

关于波士顿制药

Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced and committed drug development team to advance a portfolio of highly differentiated therapies that may address important unmet medical needs in serious liver diseases, with MASH as the focus of its lead asset.

波士顿制药（Boston Pharmaceuticals）是一家临床阶段的生物制药公司，它利用经验丰富且专注的药物开发团队推进高度分化的疗法组合，这些疗法可能解决严重肝病中未满足的重要医疗需求，MASH是其主要资产。

The Company has significant expansion opportunities through its portfolio of promising drug development candidates that were acquired through partnerships with proven, innovative biotechnology and pharmaceutical companies. Boston Pharmaceuticals applies rigorous decision making to advance programs to deliver differentiated medicines to patients in need of new options, while creating value for all parties involved in the journey..

该公司通过与经过验证的创新生物技术和制药公司的合作获得了一系列有前途的药物开发候选人，从而拥有重大的扩张机会。波士顿制药公司（Boston Pharmaceuticals）采用严格的决策来推进项目，为需要新选择的患者提供差异化药物，同时为旅程中的所有各方创造价值。。

For more information, please visit www.bostonpharmaceuticals.com and follow us on LinkedIn.

有关更多信息，请访问www.bostonpharmaticals.com并在LinkedIn上关注我们。

About B-Flexion

关于B屈曲

Boston Pharmaceuticals is a portfolio company of B-Flexion, a private entrepreneurial investment firm that partners with sophisticated capital to deliver exceptional value over the generations, while also contributing positively to society. Chaired by Ernesto Bertarelli and with offices across Europe and the United States, B-Flexion seeds, acquires and builds investment partnerships, principally in the fields of Private Equity, Venture & Growth Capital, Real Assets, Hedge Funds, Credit, and Public Securities.

波士顿制药公司（Boston Pharmaceuticals）是B-Flexion的投资组合公司，B-Flexion是一家私人创业投资公司，与成熟的资本合作，为几代人带来非凡的价值，同时也为社会做出了积极贡献。B-Flexion由Ernesto Bertarelli担任主席，在欧洲和美国设有办事处，收购并建立投资伙伴关系，主要涉及私募股权、风险与增长资本、房地产、对冲基金、信贷和公共证券领域。

As well as these partnerships, B-Flexion makes principal investments in operating businesses in transformative industries with a focus on Healthcare, Planet, Consumer and Technology..

除了这些合作伙伴关系，B-Flexion还主要投资于转型行业的运营业务，重点关注医疗保健、地球、消费者和技术。。

For more information, please visit www.bflexion.com.

有关更多信息，请访问www.bflexion.com。